JP2025506821A - 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 - Google Patents

活性薬剤の経口投与用の酸中和ポリマーを含む製剤 Download PDF

Info

Publication number
JP2025506821A
JP2025506821A JP2024550241A JP2024550241A JP2025506821A JP 2025506821 A JP2025506821 A JP 2025506821A JP 2024550241 A JP2024550241 A JP 2024550241A JP 2024550241 A JP2024550241 A JP 2024550241A JP 2025506821 A JP2025506821 A JP 2025506821A
Authority
JP
Japan
Prior art keywords
receptor
glp
composition
active agent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506821A5 (cg-RX-API-DMAC7.html
Inventor
グレゴリー バーシュテイン
コンスタンティン イティン
ヒレル ガリッツァー
フィリップ エム シュワルツ
Original Assignee
エンテラ バイオ エルティーディー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンテラ バイオ エルティーディー. filed Critical エンテラ バイオ エルティーディー.
Publication of JP2025506821A publication Critical patent/JP2025506821A/ja
Publication of JP2025506821A5 publication Critical patent/JP2025506821A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024550241A 2022-02-24 2023-02-23 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 Pending JP2025506821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313363P 2022-02-24 2022-02-24
US63/313,363 2022-02-24
PCT/IL2023/050192 WO2023161934A1 (en) 2022-02-24 2023-02-23 Formulations comprising acid-neutralizing polymer for oral administration of active agents

Publications (2)

Publication Number Publication Date
JP2025506821A true JP2025506821A (ja) 2025-03-13
JP2025506821A5 JP2025506821A5 (cg-RX-API-DMAC7.html) 2026-01-07

Family

ID=87765060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550241A Pending JP2025506821A (ja) 2022-02-24 2023-02-23 活性薬剤の経口投与用の酸中和ポリマーを含む製剤

Country Status (10)

Country Link
US (1) US20250186558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482507A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506821A (cg-RX-API-DMAC7.html)
KR (1) KR20240152915A (cg-RX-API-DMAC7.html)
CN (1) CN119053335A (cg-RX-API-DMAC7.html)
AU (1) AU2023226618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251862A1 (cg-RX-API-DMAC7.html)
IL (1) IL315198A (cg-RX-API-DMAC7.html)
MX (1) MX2024010387A (cg-RX-API-DMAC7.html)
WO (1) WO2023161934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2008070543A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
WO2016128972A1 (en) * 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
MX2019001850A (es) * 2016-08-17 2019-05-15 Entera Bio Ltd Formulaciones para administracion oral de principios activos.
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
CN112587496A (zh) * 2020-12-16 2021-04-02 江苏海洋大学 一种艾塞那肽肠溶胶囊及其制备方法

Also Published As

Publication number Publication date
CN119053335A (zh) 2024-11-29
WO2023161934A1 (en) 2023-08-31
MX2024010387A (es) 2024-09-04
EP4482507A1 (en) 2025-01-01
IL315198A (en) 2024-10-01
US20250186558A1 (en) 2025-06-12
EP4482507A4 (en) 2026-02-18
CA3251862A1 (en) 2023-08-31
AU2023226618A1 (en) 2024-10-03
KR20240152915A (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
JP7546622B2 (ja) 活性薬剤の経口投与のための製剤
US20260124281A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
JP2025506555A (ja) 酸中和ポリマーを含む、グルカゴン様ペプチド-1とその類似体の、経口投与用の製剤
KR20240152915A (ko) 활성제의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
WO2023161938A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
KR20260061220A (ko) 활성 제제의 경구 투여를 위한 산 중화 중합체성 및 비중합체성 물질의 조합을 포함하는 제형
JP2025505862A (ja) 酸中和ポリマーを含む、グルカゴン様ペプチド-2の経口投与用の製剤
WO2025046590A1 (en) Formulations for oral administration of active agents
WO2023161935A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161936A1 (en) Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
HK40101653A (en) Formulations for oral administration of active agents
HK40101429A (en) Formulations for oral administration of active agents
BR122024010024A2 (pt) Forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária, e, kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241010

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251223